Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease

Launched by TAN TOCK SENG HOSPITAL · Feb 19, 2021

Keywords

ClinConnect Summary

Cardiovascular disease accounts for more than 50% of end-stage renal disease (ESRD) deaths. The reported cardiovascular death rates in patients receiving dialysis are substantially higher than in the general population. Cardiovascular mortality in ESRD is particularly high after acute myocardial infarction, but it is also elevated in ESRD patients with other forms of atherosclerotic vascular disease (eg, chronic coronary artery disease, strokes, transient ischemic attacks, and peripheral arterial disease). Left ventricular hypertrophy and dilation are associated with increased cardiovascula...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Provision of informed consent prior to any study specific procedures.
• • Female or male aged ≥ 21 years.
• • Undergoing haemodialysis for end stage renal disease regardless of cause and previous cardiac events.
• Exclusion Criteria:
• • Diagnosis of Type 1 diabetes mellitus.
• • Pregnant or planning pregnancy or breast-feeding patients.
• • Any clinical condition that would jeopardize patient safety while participating in this clinical trial.
• • Intake of an investigational drug or participating in another clinical trial involving an investigational drug.
• • Life limiting disease other than ESRD with life expectancy estimated to be less than 12 month.